A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Study ID
- NCT05079919
- Phase
- PHASE3
- Status
- Completed
Conditions
- Severe Hypertriglyceridemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Olezarsen — DRUGOlezarsen will be administered by SC injection.
- Placebo — DRUGOlezarsen-matching placebo will be administered by SC injection.
Study Details
The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Key Dates
- Start date
- Oct 25, 2021
- Status verified
- Feb 2026
- Primary completion
- Oct 22, 2024
- Completion
- Jul 8, 2025
Study Design
- Enrollment
- 617 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: OlezarsenOlezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
- Placebo Comparator: PlaceboOlezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
Primary Outcome Measure
Percent Change from Baseline in Fasting TG Compared to Placebo [ Time Frame: Baseline and Month 6 ]
Locations (56)
Find similar trials in Birmingham, AL
By research site
Related Studies
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPHASE3 · Recruiting · Arrowhead Pharmaceuticals · Los Angeles, California
- A Study of Solbinsiran (LY3561774) in Participants With Severe HypertriglyceridemiaPHASE2 · Recruiting · Eli Lilly and Company · Phoenix, Arizona
- A Study to Assess the Safety, Tolerability and Efficacy of ION775PHASE2 · Recruiting · Ionis Pharmaceuticals, Inc. · Lincoln, California